BRCA1/2胚系突变卵巢癌患者临床家系特征及高危人群预防现状
该研究纳入77例BRCA1/2胚系突变卵巢癌患者,比较BRCA1与BRCA2突变组的临床特征与生存,并对37个家系81位亲属进行基因检测和预防指导。BRCA1组发病更早且HBOC家族史比例更高,家系中检出47例突变携带者,但女性携带者接受RRSO者极少,携带者对RRSO存在决策困境。
要点
- BRCA1突变卵巢癌患者中位发病年龄52岁,早于BRCA2组的56岁。
- BRCA1携带者HBOC家族史占43.8%,高于BRCA2组的17.2%。
- 81位亲属中检出47例BRCA突变携带者,仅2位女性接受RRSO。
核心结论
- 中国BRCA1/2突变携带者对RRSO所致医源性绝经顾虑较重,高危人群卵巢癌手术预防存在决策困境。
- 国内BRCA1/2突变卵巢癌患者发病年龄较晚,适宜国内女性的手术时机仍需进一步探讨。
研究设计与样本
- 回顾性纳入2015—2024年解放军总医院妇产医学部77例经基因检测确认BRCA1/2胚系突变的卵巢癌患者,分为BRCA1组48例和BRCA2组29例。
- 采集家系信息并对来自37个家系的81位亲属进行BRCA基因检测,结合家族史分析家系特征并提供预防指导。
主要发现
- 77例患者发病年龄19~78岁,中位55岁;BRCA1组中位52岁,早于BRCA2组的56岁(P<0.05)。
- BRCA1组HBOC家族史43.8%(21/48),高于BRCA2组的17.2%(5/29,P<0.05)。
- 两组生育情况、BMI、乳腺癌个人史及治疗前CA125水平差异无统计学意义(P>0.05)。
- BRCA1组初始治疗中位PFS为21.8个月,BRCA2组为20.7个月。
- 81位亲属中检出47位BRCA突变携带者,63.8%(30/47)来自无HBOC家族史家系;31位女性携带者中仅2位接受RRSO。
关键数值与推荐
- BRCA1突变组中位发病年龄52岁,BRCA2组56岁(P<0.05)。
- BRCA1组HBOC家族史43.8%(21/48),BRCA2组17.2%(5/29,P<0.05)。
- BRCA1组初始治疗中位PFS 21.8个月,BRCA2组20.7个月。
- 81位亲属中47位为BRCA突变携带者,其中63.8%(30/47)来自无HBOC家族史家系。
- 31位女性突变携带者中仅2位接受RRSO;8位携带者手术意向平均2.6分(5分制),6位倾向延迟至自然绝经后行RRSO。
临床怎么用
- 对BRCA1/2胚系突变卵巢癌患者应详细采集家系史并对高危亲属开展BRCA基因检测。
- 检测不应仅限有HBOC家族史家系,因多数突变携带者来自无家族史家系。
- 需针对携带者对RRSO医源性绝经的顾虑进行个体化咨询与决策支持。
局限性
- 单中心回顾性研究,样本量有限。
- 携带者手术意向调查样本量小(8位携带者)。
- 中国女性BRCA突变者RRSO最佳手术时机尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics of breast cancer susceptibility gene (BRCA) germline mutation carriers with ovarian cancer, collect family history information, screen for potential BRCA mutation carriers among family members, and provide preventive guidance for high-risk populations of ovarian cancer. Methods: A total of 77 patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer, hereinafter collectively referred to as ovarian cancer) who were treated at the Department of Obstetrics and Gynecology, Chinese PLA General Hospital between 2015 and 2024 and confirmed to carry germline mutations in the BRCA1/2 genes through genetic testing were selected. According to the test results, they were divided into the BRCA1 mutation group (48 cases) and the BRCA2 mutation group (29 cases). The clinical baseline data, pathological characteristics, treatment efficacy, and survival outcomes were compared between the two groups. Family history information was collected, and BRCA genetic testing was performed on 81 relatives from 37 families. Family characteristics were analyzed in combination with family history and genetic testing results, and preventive guidance was provided to high-risk populations. Results: The age at onset of the 77 patients ranged from 19 to 78 years, with a median age of 55 years. The age at onset in the BRCA1 mutation group ranged from 19 to 74 years, with a median age of 52 years, which was earlier than the median age of 56 years in the BRCA2 mutation group. 43.8% (21/48) of BRCA1 carriers had a family history of hereditary breast and ovarian cancer syndrome (HBOC), which was 1.5 times higher than that in the BRCA2 group (17.2%, 5/29, P<0.05). There were no statistically significant differences in fertility status, body mass index (BMI), personal history of breast cancer, and pre-treatment carbohydrate antigen 125 (CA125) levels between the two groups (P>0.05). The median progression-free survival (PFS) for initial treatment was 21.8 months in BRCA1 mutation patients and 20.7 months in BRCA2 mutation patients. Among the 81 relatives, 47 BRCA gene mutation carriers were detected, of whom 63.8% (30/47) were from families without a family history of HBOC. Among 31 female mutation carriers, only 2 underwent risk-reducing salpingo-oophorectomy (RRSO). A survey of the general population showed that 78.5% of non-carrier women would accept prophylactic surgery, while the average surgical intention score among carriers was only 2.6 (on a 5-point scale), with 75.0% preferring to delay RRSO until after natural menopause. Conclusions: Chinese BRCA1/2 mutation carriers have significant concerns regarding iatrogenic menopause caused by RRSO, creating a decision-making dilemma for surgical prevention of ovarian cancer in high-risk populations. The age at onset of ovarian cancer in Chinese BRCA1/2 mutation carriers is relatively late compared with international data, and the optimal timing of surgery for Chinese women still requires further investigation. Developing a localized surgical timing prediction model may help advance ovarian cancer prevention and treatment efforts. 目的: 分析乳腺癌相关基因(BRCA)胚系突变卵巢癌患者的临床特征,并进行家系信息采集,筛查家系亲属中潜在的BRCA突变携带者,针对卵巢癌患病高危人群予以预防指导。 方法: 选取2015—2024年在解放军总医院妇产医学部接受治疗,并通过基因检测确认携带BRCA1/2基因胚系突变的77例卵巢癌(包含输卵管癌、盆腔腹膜癌,后文统称卵巢癌)患者,根据检测结果分为BRCA1突变组(48例)和BRCA2突变组(29例),比较两组患者的临床基线资料、病理特征、治疗效果及生存结局。采集患者家系信息,对来自37个家系的81位患者亲属进行BRCA基因检测,结合家族史情况和基因检测结果分析家系特征,对高危人群进行预防指导。 结果: 77例患者发病年龄波动于19~78岁,中位发病年龄55岁。BRCA1突变组发病年龄为19~74岁,中位发病年龄52岁,早于BRCA2突变组的56(37~78)岁(P<0.05)。43.8%(21/48)的BRCA1携带者具有遗传性乳腺癌-卵巢癌综合征(HBOC)家族史,较BRCA2组高1.5倍(17.2%,5/29,P<0.05)。两组患者的生育情况、体质指数、乳腺癌个人史及治疗前糖类抗原125水平比较,差异无统计学意义(P>0.05)。BRCA1突变患者初始治疗的中位无进展生存时间(PFS)为21.8个月,BRCA2突变患者初始治疗的中位PFS为20.7个月。81位患者亲属中检测出47位BRCA基因突变携带者,其中63.8%(30/47)来自无HBOC家族史的家系。31位女性突变携带者中仅2位接受预防性双侧卵巢-输卵管切除术(RRSO)。健康人群调查显示,78.5%(128/163)非携带女性可接受预防性手术,而8位BRCA1/2突变携带者群体手术意向平均仅2.6分(5分制),6位(6/8)倾向延迟至自然绝经后施行RRSO。 结论: 中国BRCA1/2突变携带者对RRSO手术带来的医源性绝经顾虑较重,高危人群卵巢癌的手术预防存在决策困境。国内BRCA1/2 突变卵巢癌患者卵巢癌发病年龄较晚,适宜国内女性的手术时机仍需进一步探讨,开发本土化手术时机判定模型有助于推动卵巢癌防治工作。.
引用
- Chen MY, Zhou JL, Zhang XY, et al. [Clinical and familial characterisation of ovarian cancer patients with germline mutations in the BRCA1/2 gene and the current status of prevention in high-risk groups]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42477928. doi:10.3760/cma.j.cn112152-20250821-00411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。